ArticleFrontiers in neurology
Elevated fibroblast growth factor 23 levels predict cardiovascular and cerebrovascular events in acute ischaemic stroke patients.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The bone-cerebrovascular axis: effects of bone aging on neurovascular dysfunction and neurodegeneration.The Journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies on fibroblast growth factor 23 (FGF23) and acute ischaemic stroke (AIS) have been conducted, but some of the results are conflicting. Therefore, the objective of this study was to assess whether baseline FGF23 levels are associated with the occurrence of major adverse cardiovascular and cerebrovascular events (MACCEs) in AIS patients. Methods: In this study, 394 patients with AIS were enrolled. A total of 130 people who underwent health check-ups in our hospital composed the control group. The study endpoint was the first occurrence of MACCEs outside the hospital. Serum FGF23 levels were measured using a commercial human enzyme-linked immunosorbent assay kit. Results: Eighty five MACCEs were recorded during a median follow-up of 43 months. Serum FGF23 levels were found to be significantly greater in the AIS group than in the control group (525.14 ± 167.40 pg./mL vs. 338.62 ± 161.71 pg./mL, Conclusion: Elevated baseline serum FGF23 level was considered a valid predictor of MACCEs in patients with AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.